Free Trial
NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

Tenax Therapeutics logo
$5.90 -0.02 (-0.34%)
Closing price 03:58 PM Eastern
Extended Trading
$5.94 +0.04 (+0.76%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tenax Therapeutics Stock (NASDAQ:TENX)

Key Stats

Today's Range
$5.90
$6.01
50-Day Range
$5.62
$6.24
52-Week Range
$3.25
$7.89
Volume
18,913 shs
Average Volume
28,811 shs
Market Capitalization
$26.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Buy

Company Overview

Tenax Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

TENX MarketRank™: 

Tenax Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 802nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tenax Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Tenax Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tenax Therapeutics is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tenax Therapeutics is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tenax Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Tenax Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.22% of the float of Tenax Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tenax Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tenax Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving.
  • Dividend Yield

    Tenax Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tenax Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.22% of the float of Tenax Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tenax Therapeutics has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tenax Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving.
  • News Sentiment

    Tenax Therapeutics has a news sentiment score of -0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Tenax Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.70% of the stock of Tenax Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 1.67% of the stock of Tenax Therapeutics is held by institutions.

  • Read more about Tenax Therapeutics' insider trading history.
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TENX Stock News Headlines

Leerink Partnrs Has Negative Forecast for TENX Q3 Earnings
William Blair Brokers Decrease Earnings Estimates for TENX
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst
Equities Analysts Set Expectations for TENX FY2028 Earnings
TENX Tenax Therapeutics, Inc. - Seeking Alpha
See More Headlines

TENX Stock Analysis - Frequently Asked Questions

Tenax Therapeutics' stock was trading at $6.19 at the beginning of 2025. Since then, TENX shares have decreased by 2.7% and is now trading at $6.02.

Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its earnings results on Wednesday, August, 13th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.23.

Tenax Therapeutics shares reverse split on Wednesday, January 3rd 2024.The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/13/2025
Today
8/26/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TENX
CIK
34956
Employees
9
Year Founded
1967

Price Target and Rating

High Price Target
$20.00
Low Price Target
$14.00
Potential Upside/Downside
+182.4%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$17.60 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.34%
Return on Assets
-30.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
41.89
Quick Ratio
41.89

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$26.99 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
4,560,000
Free Float
4,393,000
Market Cap
$27.45 million
Optionable
Not Optionable
Beta
1.46

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TENX) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners